NIH RFA · NHLBI · R33
RFA-HL-26-016: Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Enabling Technologies and Transformative Platforms initiative will support needed to rigorously validate transformative, multi-use platforms or technologies that can enable. Well-suited applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development,…
- NOFO number
- RFA-HL-26-016
- Type
- RFA
- Activity code
- R33
- Primary institute
- NHLBI · National Heart, Lung, and Blood Institute
- Clinical trials
- Not Allowed
- Posted
- Nov 22, 2024
- Opens
- Jan 11, 2025
- Expires
- Dec 24, 2027
RFA-HL-26-016 due dates
4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 11, 2025 | February 11, 2025 | April 21, 2025 | July 2025 | October 2025 | December 2025 |
| June 18, 2025 | June 18, 2025 | August 21, 2025 | November 2025 | January 2026 | April 2026 |
| October 21, 2025 | October 21, 2025 | December 22, 2025 | March 2026 | May 2026 | July 2026 |
| February 11, 2026 | February 11, 2026 | April 21, 2026 | July 2026 | October 2026 | December 2026 |
| June 18, 2026 | June 18, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 21, 2026 | October 21, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 11, 2027 | February 11, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 17, 2027 | June 17, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 21, 2027 | October 21, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under RFA-HL-26-016
NIH RePORTER lists 4 projects funded under RFA-HL-26-016 in FY2022–FY2026, with $1.9M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
4
Distinct projects, FY2022–FY2026
New awards
4
Type 1 (new project) award records
NIH funding
$1.9M
Award dollars under RFA-HL-26-016, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 4 | 4 | $1.9M |
Institutions with the most funding
- Icahn School of Medicine at Mount Sinai$571K · 1 project
- Stanford University$509K · 1 project
- 3d Bioanalytix, Inc.$421K · 1 project
- Halcyon Biomedical, Inc.$352K · 1 project
Funding institutes
- NHLBI$1.9M · 4
Activity codes funded
- R334 records
Most recent new awards
- Development and validation of a cell separation platform technology (opens NIH RePORTER)
Halcyon Biomedical, Inc. · 1R33HL183009-01 · NHLBI · Notice Sep 4, 2026
$352KR33
- High-throughput, multi-parametric assessment of cardiomyocyte viscoelasticity and contractility to enable HFpEF drug discovery (opens NIH RePORTER)
Stanford University · 1R33HL187274-01 · NHLBI · Notice Aug 12, 2026
$509KR33
- A Transformative Structural Proteomics Platform for Early Detection of Misfolding-Driven Cardiovascular Diseases (opens NIH RePORTER)
3d Bioanalytix, Inc. · 1R33HL185603-01 · NHLBI · Notice Jun 25, 2026
$421KR33
- A streamlined base editor reengineering platform to enhance gene editing specificity and selectivity (opens NIH RePORTER)
Icahn School of Medicine at Mount Sinai · 1R33HL185498-01 · NHLBI · Notice Jun 23, 2026
$571KR33
What its predecessor RFA-HL-23-010 funded
RFA-HL-26-016 reissues RFA-HL-23-010. Its funding history is the best guide to who wins under this program: 10 projects and $9.0M in FY2022–FY2026.
Projects funded
10
Distinct projects, FY2022–FY2026
New awards
9
Type 1 (new project) award records
NIH funding
$9.0M
Award dollars under RFA-HL-23-010, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 3 | 3 | $1.5M |
| FY2024 | 7 | 4 | $3.3M |
| FY2025 | 6 | 2 | $2.8M |
| FY2026 | 3 | 0 | $1.4M |
Institutions with the most funding
- Brigham and Women's Hospital$1.1M · 1 project
- Vanderbilt University$963K · 1 project
- University of Massachusetts Amherst$959K · 1 project
- University of Pittsburgh at Pittsburgh$957K · 1 project
- Massachusetts General Hospital$951K · 1 project
- University of California, San Diego$944K · 1 project
- Northwestern University$924K · 1 project
- Stanford University$908K · 1 project
Funding institutes
- NHLBI$9.0M · 19
Activity codes funded
- R3319 records
Most recent new awards
- Drug Coated Balloon Peptide Delivery to Block Post-angioplasty Restenosis in PAD (opens NIH RePORTER)
Vanderbilt University · 1R33HL181752-01 · NHLBI · Notice Aug 19, 2025
$490KR33
- Development of platform technology to measure kinetics and equilibrium concentration of sickle hemoglobin polymerization in single RBCs for drug potency assessment and patient risk stratification (opens NIH RePORTER)
Massachusetts General Hospital · 1R33HL173898-01A1 · NHLBI · Notice Mar 18, 2025
$484KR33
- Flexible bioelectronics platform converging capillary-like delivery network and sensing feedback network for improving cardiac tissue engineering (opens NIH RePORTER)
University of Massachusetts Amherst · 1R33HL175683-01 · NHLBI · Notice Sep 6, 2024
$488KR33
- A Novel Ticagrelor Coated Stent to Eliminate the Need for Dual Anti Platelet Therapy Post PCI (opens NIH RePORTER)
University of Pittsburgh at Pittsburgh · 1R33HL171775-01 · NHLBI · Notice May 6, 2024
$481KR33
- Towards systematic analysis of cardiac voltage-gated sodium channel beta subunit function (opens NIH RePORTER)
University of Iowa · 1R33HL168768-01A1 · NHLBI · Notice Dec 29, 2023
$466KR33
- Advancement of an Impending Hospitalization Detection Platform (opens NIH RePORTER)
University of California, San Diego · 1R33HL168785-01A1 · NHLBI · Notice Dec 26, 2023
$474KR33
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under RFA-HL-26-016. Contact the program officer at the institute that fits your research before applying.
- NHLBI · National Heart, Lung, and Blood Institute
- none
Related notices
Jan 28, 2026 · NOT-OD-26-029
NIH Removing AIDS Application Due Dates from NOFOs.
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets must not exceed 350,000 direct costs per year.The total budget must reflect the actual needs of the proposed project and annual project budgets must reflect the actual costs anticipated in each year.
- Project period
- The maximum project period is two years. The scope of the project should determine the project period. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- NHLBI intends to commit total costs of up to 2,156,000 in FY 2026, 2,156,000 in FY 2027, and 2,156,000 in FY 2028. NHLBI expects to fund up to 4 new awards in FY 2026, 4 new awards in FY 2027, and 4 new awards in FY 2028, for a total of up to 12 new awards.The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of RFA-HL-23-010.
- Companion NOFOs: RFA-HL-26-017, RFA-HL-26-018, RFA-HL-26-019, RFA-HL-26-020.
Other open NOFOs for R33
- RFA-HL-26-017Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-018Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-019Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-020Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- PAR-27-011Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)NHLBI · next due Feb 1, 2027
- PAR-25-025NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)NHLBI
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.